Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUYN26)

Drug Name

IMC-CS4 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Colony stimulating factor-1 receptor (CSF-1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
RG7155	DM8JMNL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
MCS-110	DM0CL4I	Bone metastases	2D50	Phase 2	[2]
JNJ-40346527	DM219SF	Hodgkin lymphoma	2B30	Phase 2	[5]
PD-360324	DM6F5EV	Rheumatoid arthritis	FA20	Phase 2	[6]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[7]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Colony stimulating factor-1 receptor (CSF-1R)	TT731LW	E9PEK4_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01346358) A Study of IMC-CS4 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Company report (Array)
4	Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.
5	An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50.
6	Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70.
7	Company report (Five Prime Therapeutics)